Intensity Therapeutics (INTS) Expected to Release Quarterly Earnings on Thursday

Intensity Therapeutics (NASDAQ:INTS) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Intensity Therapeutics to announce earnings of ($0.8725) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.08) by $0.12. On average, analysts expect Intensity Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Intensity Therapeutics Price Performance

Intensity Therapeutics stock traded down $0.04 during mid-day trading on Tuesday, reaching $4.21. The company had a trading volume of 2,341 shares, compared to its average volume of 43,937. The stock’s 50-day simple moving average is $4.27 and its 200-day simple moving average is $5.90. Intensity Therapeutics has a 1 year low of $3.51 and a 1 year high of $43.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market capitalization of $11.38 million, a P/E ratio of -0.74 and a beta of 2.76.

Wall Street Analyst Weigh In

Several research firms recently weighed in on INTS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.50.

Hedge Funds Weigh In On Intensity Therapeutics

Institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC purchased a new stake in Intensity Therapeutics during the 4th quarter worth about $41,000. State Street Corp lifted its holdings in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after purchasing an additional 201,357 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics during the 4th quarter worth about $26,000. 3.74% of the stock is owned by institutional investors and hedge funds.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.